Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Sank Today

By Keith Speights - Feb 22, 2021 at 3:58PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech announced good news. But investors could be worried about external factors.

What happened

Shares of Novavax (NVAX -7.50%) were sinking 12.5% lower as of 3:32 p.m. EST on Monday. The biotech announced that it has completed enrollment of a late-stage study of COVID-19 vaccine NVX-CoV2373 in the U.S. and Mexico. That's good news, so why did the stock fall? There are two likely reasons.

First, the overall stock market declined on Monday. High-flying stocks like Novavax tend to drop more than the overall market does on a down day. Second, some investors could be concerned that a potential U.S. Emergency Use Authorization (EUA) later this week for Johnson & Johnson's (JNJ 0.70%) COVID-19 vaccine could limit Novavax's opportunities.

Stock chart going down with coronavirus virions

Image source: Getty Images.

So what

Clinical-stage biotech stocks like Novavax are usually volatile. It's not surprising that the company's shares would fall on a day when the Nasdaq Composite Index slid nearly 2% lower. The best thing for investors to do is ignore the noise when this happens.

What about the potential that J&J could win EUA for its vaccine and hurt Novavax's prospects? The chances for the big healthcare company to receive a positive recommendation from the U.S. Food and Drug Administration (FDA) advisory committee on Thursday appear to be good. J&J also should be in a strong position to get a thumbs-up from the FDA following the committee's vote.

However, good news for J&J doesn't necessarily translate to bad news for Novavax. Today's report that enrollment completed in Novavax's late-stage study in the U.S. and Mexico should mean that results will be available relatively soon. If those results are as positive as Novavax's U.K. study data, the biotech should also be on track to secure EUA for its COVID-19 vaccine in the United States. Novavax already has a supply deal with the U.S. government for 100 million doses.

Now what

Several regulatory agencies, including the European Medicines Agency and the U.K. Medicines and Healthcare products Regulatory Agency, have already begun a rolling review process for authorization of NVX-CoV2373. The main thing to watch with Novavax over the short term is the potential for the company's COVID-19 vaccine to secure EUA from one or more of these regulatory agencies.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$48.00 (-7.50%) $-3.89
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$178.08 (0.70%) $1.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.